06.10.2011
NeuroSeach A/S (NEUR) has received information from Porter Orlin LLC, New York, that the company has increased its voting rights in NeuroSearch A/S attached to shares owned by other companies.
Hereafter, Porter Orlin LLC administers a total of 1,306,667 shares of DKK 20 nominal value corresponding to a total ownership and voting rights of 5.32%.
Patrik Dahlen
CEO
Contact person
René Schneider, EVP & CFO, telephone: +45 4460 8700 or +45 2911 2097
About NeuroSearch
NeuroSearch A/S is a European-based biopharmaceutical company listed on NASDAQ OMX Copenhagen A/S (NEUR) and specialising in central nervous system (CNS) disorders. The vision is to develop NeuroSearch into a profitable specialty pharmaceutical company. The strategy is primarily to complete the development and subsequently to market Huntexil®, a unique drug in Phase III for the treatment of the motor symptoms of Huntington’s disease.
Attachments
